## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `retatrutide-glp1-agonists`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `retatrutide-glp1-agonists` v4 · content_hash `dcd6b7bdb3704e6e…` · thread_head genesis · 2 DIVs
- **thesis (c_map_retatrutide-glp1-agonist):** Combinatorial mapping (transparent): retatrutide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence_factor(0.40); catalog.degen_score for GLP-1 agonists (class).
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `retatrutide-glp1-agonists`
- **title:** retatrutide glp1 agonists
- **url:** https://miscsubjects.com/a/retatrutide-glp1-agonists
- **register:** standard
- **updated:** 2026-07-17T02:41:16.988Z

## Body

## Overview
Evidence is being populated by Grok web search.

## Claims (1)

- **c_map_retatrutide-glp1-agonist** [runtime w=0.35] Combinatorial mapping (transparent): retatrutide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence_factor(0.40); catalog.degen_score for GLP-1 agonists (class).

## Voxel graph (1 atoms · 0 edges)
- full graph: https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (22)
- chain valid: yes · head: `7b99e640159338e3`

### s1 · pubmed · ok
- title: Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...
- url: https://pubmed.ncbi.nlm.nih.gov/41723268/
- summary: 2026 study showing anti-obesity effects of retatrutide and comparators in MC4R KO mice.
- quote: Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.
- hash: `d1683ea5935261c4`

### s2 · pubmed · ok
- title: Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...
- url: https://pubmed.ncbi.nlm.nih.gov/40685589/
- summary: 2025/2026 comparison of GLP-1 agonists including retatrutide on efficacy and safety.
- quote: Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.
- hash: `91c54969fdb55658`

### s3 · pubmed · ok
- title: Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...
- url: https://pubmed.ncbi.nlm.nih.gov/40291085/
- summary: Meta or review on retatrutide's effects in obesity.
- quote: Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.
- hash: `d09058577dab1f1a`

### s4 · pubmed · ok
- title: Retatrutide-A Game Changer in Obesity Pharmacotherapy
- url: https://pubmed.ncbi.nlm.nih.gov/40563436/
- summary: 2025 review highlighting retatrutide as triple agonist for obesity and T2DM.
- quote: Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...
- hash: `d6970f6158717086`

### s5 · clinical_trial · ok
- title: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
- url: https://clinicaltrials.gov/study/NCT05882045
- summary: Ongoing phase 3 trial on retatrutide for obesity with CVD.
- quote: The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).
- hash: `71b2363f74d8cdb0`

### s6 · pubmed · ok
- title: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)
- url: https://pubmed.ncbi.nlm.nih.gov/42250575/
- summary: 2026 phase 3 trial results in T2D patients.
- quote: Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.
- hash: `07fd561d3e724bd7`

### s7 · review · ok
- title: Retatrutide in type 2 diabetes mellitus and obesity: an overview
- url: https://pubmed.ncbi.nlm.nih.gov/41785010/
- summary: 2026 review on retatrutide for T2DM and obesity, noting significant weight loss up to 16.94% in T2DM subjects.
- quote: Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).
- hash: `0413b2dceecc121c`

### s8 · pubmed · ok
- title: Retatrutide and the Paradigm Shift in Multi-Hormonal ...
- url: https://pubmed.ncbi.nlm.nih.gov/41545327/
- summary: 2026 PubMed article on retatrutide as a triple agonist for obesity treatment.
- quote: Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.
- hash: `520b95b711b028b7`

### s9 · pubmed · ok
- title: Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes
- url: https://pubmed.ncbi.nlm.nih.gov/42135195/
- summary: 2026 study on retatrutide's effects on lipids and metabolites in obesity/T2D.
- quote: retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.
- hash: `1192147733cc9b9d`

### s10 · review · ok
- title: Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review
- url: https://pubmed.ncbi.nlm.nih.gov/42108533/
- summary: 2026 comprehensive review on retatrutide for CKM syndrome, including liver disease benefits.
- quote: Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.
- hash: `be593910255a4e73`

### s11 · pubmed · ok
- title: Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models
- url: https://pubmed.ncbi.nlm.nih.gov/41741376/
- summary: 2026 preclinical study on metabolic benefits of retatrutide in MASH models.
- quote: Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.
- hash: `b61d2944fb0e25dd`

### s12 · clinical_trial · ok
- title: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)
- url: https://clinicaltrials.gov/study/NCT07232719
- summary: New 2026 Phase 3 trial NCT07232719 for retatrutide in obesity/overweight.
- quote: The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.
- hash: `40117b02abb718fa`

### s13 · clinical_trial · ok
- title: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)
- url: https://clinicaltrials.gov/study/NCT06662383
- summary: New Phase 3 trial comparing retatrutide to tirzepatide in obesity.
- quote: The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.
- hash: `1a0ff0178209f4d9`

### s14 · pubmed · ok
- title: The First Triple Agonist for Antiobesity: Retatrutide
- url: https://pubmed.ncbi.nlm.nih.gov/39724554/
- summary: Overview of retatrutide as the first triple agonist for antiobesity treatment.
- quote: One such drug is retatrutide , which is a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent ...
- hash: `692b8380b96c0c32`

### s15 · pubmed · ok
- title: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- url: https://pubmed.ncbi.nlm.nih.gov/38858523/
- summary: Phase 2a trial results on retatrutide for MASLD.
- quote: Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors.
- hash: `bfd3b1ac48a7c655`

### s16 · pubmed · ok
- title: Effects of retatrutide on body composition in people with type 2 diabetes
- url: https://pubmed.ncbi.nlm.nih.gov/40609566/
- summary: Body composition improvements with retatrutide in T2D patients.
- quote: In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.
- hash: `047c02d60235f2bf`

### s17 · pubmed · ok
- title: Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
- url: https://pubmed.ncbi.nlm.nih.gov/41090431/
- summary: Design of TRIUMPH trials for retatrutide in multiple conditions.
- quote: Retatrutide , a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors.
- hash: `a8ebd7ce7d6aab63`

### s18 · pubmed · ok
- title: Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis
- url: https://pubmed.ncbi.nlm.nih.gov/39817343/
- summary: Meta-analysis of retatrutide efficacy and safety for obesity.
- quote: Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials.
- hash: `f625da21766730da`

### s19 · pubmed · ok
- title: Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
- url: https://pubmed.ncbi.nlm.nih.gov/40094000/
- summary: Preclinical evidence on retatrutide reducing obesity-linked cancer progression.
- quote: Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
- hash: `c1dbf6e8363dc608`

### s20 · pubmed · ok
- title: Triple Agonism Based Therapies for Obesity
- url: https://pubmed.ncbi.nlm.nih.gov/40741227/
- summary: Review of triple agonist therapies including retatrutide.
- quote: ... retatrutide , the most advanced candidate. Recent findings: Retatrutide is the first triple agonist (acting on GLP-1 /GIP/glucagon receptors) ...
- hash: `215a294f2347346c`

### s21 · clinical_trial · ok
- title: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- url: https://clinicaltrials.gov/study/NCT05936151
- summary: Phase 2b trial on retatrutide effects on renal function in CKD.
- quote: The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).
- hash: `f05e2935b943923a`

### s22 · clinical_trial · ok
- title: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
- url: https://clinicaltrials.gov/study/NCT05931367
- summary: Phase 3 TRIUMPH-4 trial for retatrutide in OA patients.
- quote: The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or overweight and have osteoarthritis (OA) of the knee.
- hash: `7b99e640159338e3`

## Provenance (5 model passes)
- chain valid: yes · head: `f2edce16f0ccad98`

- populate-init · grok-4.3 · 2026-06-29T17:43 · hash `151871128c73`
- sources · grok-4.3 · 2026-06-29T17:43 · hash `f8d8e9c0b640`
- sources · grok-4.3 · 2026-06-29T17:43 · hash `4632ae98b947`
- sources · grok-4.3 · 2026-06-29T17:44 · hash `9878468bd5ae`
- voxel_divide · owner · 2026-07-17T02:41 · hash `f2edce16f0cc`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"retatrutide-glp1-agonists","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest retatrutide-glp1-agonists|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim retatrutide-glp1-agonists|tier|assertion`
- **iMessage ask:** `retatrutide-glp1-agonists|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `retatrutide-glp1-agonists`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/retatrutide-glp1-agonists/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*